What is Palbociclib?

Palbociclib (Palbociclib) is a drug developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. Its trade name is Ibrance. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib is the first CDK4/6 inhibitor approved for cancer treatment.

Palbociclib works by bindingATP pocket, given its low or non-existent activity against other kinases. CDK4/6 kinases participate in the G1-S transition together with the co-regulatory partner cyclin D. Thus, inhibition of this step blocks cell cycle progression in cells where this pathway acts. This step involves the phosphorylation pathway of retinoblastoma proteins and the E2F family of transcription factors. In clinical trials, the combination of palbociclib and letrozole significantly improved progression-free survival (PFS) in patients with metastatic breast cancer who had not previously received endocrine therapy.

The original drug of palbociclib has been launched in China and has entered the scope of Class B medical insurance, but it is only reimbursed for patients who meet the indications. Specifications The price of each box of 125mg*21 tablets may be more than 4,000 yuan. The price of palbociclib's original drug, 125mg*21 tablets per box, sold overseas may be around RMB 10,000 (the price may fluctuate due to exchange rates). There are also generic palbociclib drugs produced in other countries. The price of 125mg*21 tablets produced by Bangladesh pharmaceutical factory may be around 900 yuan per box (the price may fluctuate due to the exchange rate), which is cheaper. The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs.